- Home
- GOOD vs ASMB Comparison
GOOD vs ASMB Comparison
Compare GOOD & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOOD | ASMB |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 624.9M | 512.1M |
| IPO Year | 2003 | 2010 |
Fundamental Metrics
Financial Performance| Metric | GOOD | ASMB |
|---|---|---|
| Price | $9.98 | $20.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $12.88 | ★ $51.20 |
| AVG Volume (30 Days) | ★ 673.7K | 213.0K |
| Earning Date | 11-03-2026 | 11-12-2026 |
| Dividend Yield | ★ 12.18% | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $161,336,000.00 | N/A |
| Revenue This Year | $5.86 | N/A |
| Revenue Next Year | $1.99 | N/A |
| P/E Ratio | $123.88 | ★ N/A |
| Revenue Growth | ★ 8.00 | N/A |
| 52 Week Low | $9.89 | $19.20 |
| 52 Week High | $13.28 | $39.71 |
Technical Indicators
Market Signals| Indicator | GOOD | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 22.02 | 46.75 |
| Support Level | N/A | $19.25 |
| Resistance Level | $13.07 | $21.65 |
| Average True Range (ATR) | 0.35 | 1.23 |
| MACD | -0.12 | 0.32 |
| Stochastic Oscillator | 11.80 | 45.27 |
Price Performance
Historical ComparisonAbout GOOD Gladstone Commercial Corporation Real Estate Investment Trust
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.